Associate Professor in Surgery
Office:
205 Sorf, 915 S. Lasalle Street, Box 2926, Duke University Medical Center, Durham, NC 27710
Campus Mail:
DUMC Box 2926 DUMC, Durham, NC 27710
Education and Training
- Ph.D., University of California - Davis, 2004
Selected Grants
- A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled, Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effe
- A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years
- A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls
- Neutralizing Antibody Response Assessment for a Phase 2/3 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccin
- Moderna mRNA1275 P205 Trial Neutralizing Antibody Assessment
- GH-VAP: Duke Antibody Dynamics Core Extension; INV-008612 Supplement
- A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS A
- CIVICs A - Option 18A SAVE Aims 1, 2
- CIVICs A - Option 18B SAVE Aim 3
- HHSN272201800004C-Option 10
- Nonhuman Primate Option 3
- HVTN LC
- Characterizing the Neutralizing Antibody Response in SARS-CoV-2 Infected Individuals
- CIVICS Component A - Option 1
- Sublingual-parenteral vaccination to prevent oral HIV transmission in infants
- Harnessing Mucin-IgG Interactions to Enhance HIV Vaccine Function
- Comparing HIV Mucosal Targets in US and Kenyan Populations
- Primate Contract Expansion for Covid-19
- HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals: LC
- HVTN Laboratory Center: HVTN Phase 1
- Nonhuman Primate Option 22
- Antibody and viral determinants of protection against CMV infection in the gB/MF59 vaccination cohort
- HVTN Laboratory Center: HVTN 117
- HVTN Laboratory Center: HVTN 118
- HIV Vaccine Trials Network: LC P5 PF
- HVTN - A004
- Nonhuman Primate Core-Option 6
- HIV Vaccine Trials Network: LC P5 PF
- HVTN 505 Protocol
- LC: HIV Vaccine Trials Network: Phase 1 PF
- Enhancing protective antibody responses for a GM-CSF adjuvanted HIV vaccine
- Testing the ability of antibody-mucin interactions to provide vaccine function